Therefore, the introduction of RDW is a good complement to the deficiency of the pneumonia severity assessment scale and is obtained quickly without additional cost, which is different from PCT, copeptin, atrial natriuretic peptide, and other biomarkers. This evidence concerns the gene NPPA and pneumonia.